{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:46:00Z","timestamp":1785843960202,"version":"3.56.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010391","name":"Tokyo Women's Medical University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010391","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection; however, a transient decline in estimated glomerular filtration rate (eGFR), known as the \u2018\u2018initial dip\u2019\u2019, is frequently observed after initiation. Although this phenomenon reflects changes in intraglomerular hemodynamics, excessive decline may be associated with worsening renal function. Angiotensin receptor\u2013neprilysin inhibitors (ARNIs) have demonstrated renal protective effects in heart failure, but their impact on the initial dip after SGLT2 inhibitor initiation remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively evaluated the effect of prior ARNI use on the initial dip following SGLT2 inhibitor initiation in 157 patients with chronic kidney disease who newly started SGLT2 inhibitors between 2022 and 2025. Patients were classified into an ARNI group and an angiotensin receptor blocker (ARB) group. The primary outcome was the incidence of an initial dip, defined as a\u2009\u2265\u20095% decline in eGFR after SGLT2 inhibitor initiation. The secondary outcome was the change in eGFR and urine protein excretion at 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The incidence of the initial dip did not significantly differ between the ARNI and ARB groups (30.0% vs. 46.5%, p\u2009=\u20090.10). However, multivariate logistic regression analysis showed that prior ARNI use was independently associated with a lower risk of initial dip (odds ratio 0.30, 95% CI 0.10\u20130.89, p\u2009=\u20090.02). Prior ARNI use was not significantly associated with longitudinal eGFR and urine protein changes at 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prior ARNI use was associated with a lower risk of the initial eGFR dip following SGLT2 inhibitor initiation, although prospective studies are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10157-026-02928-4","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:17:08Z","timestamp":1785842228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of prior Angiotensin receptor-neprilysin inhibitor use with the initial eGFR dip after initiation of SGLT2 inhibitors in patients with chronic kidney disease"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7774-1718","authenticated-orcid":false,"given":"Yusuke","family":"Ushio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Seki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoko","family":"Sumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuka","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Makabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Nitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"15","key":"2928_CR1","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stefansson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"key":"2928_CR2","doi-asserted-by":"crossref","unstructured":"The E-KCG, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023, 388(2):117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"issue":"24","key":"2928_CR3","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"key":"2928_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25116169","author":"M Ishizaka","year":"2024","unstructured":"Ishizaka M, Yamamori Y, Hsu HH, Miyagawa Y, Takemura N, Ogawa-Yasumura M. Study on the effects of angiotensin receptor\/neprilysin inhibitors on renal haemodynamics in healthy dogs. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25116169.","journal-title":"Int J Mol Sci"},{"key":"2928_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12226993","author":"Y Saijo","year":"2023","unstructured":"Saijo Y, Okada H, Hata S, Nakajima H, Kitagawa N, Okamura T, et al. Reasons for discontinuing treatment with sodium-glucose cotransporter 2 inhibitors in patients with diabetes in real-world settings: the KAMOGAWA-A study. J Clin Med. 2023. https:\/\/doi.org\/10.3390\/jcm12226993.","journal-title":"J Clin Med"},{"issue":"7","key":"2928_CR6","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae169","volume":"17","author":"P Perrin","year":"2024","unstructured":"Perrin P, Muller C, Dimitrov Y, Chantrel F, Heitz M, Woerly A, et al. Assessment of SGLT2 inhibitors\u2019 safety and discontinuation causes in patients with advanced chronic kidney disease: insights from a real-world data analysis. Clin Kidney J. 2024;17(7):sfae169.","journal-title":"Clin Kidney J"},{"issue":"6","key":"2928_CR7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.121.058910","volume":"146","author":"C Adamson","year":"2022","unstructured":"Adamson C, Docherty KF, Heerspink HJL, de Boer RA, Damman K, Inzucchi SE, et al. Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation. 2022;146(6):438\u201349.","journal-title":"Circulation"},{"issue":"7","key":"2928_CR8","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1111\/dom.15611","volume":"26","author":"T Kanaoka","year":"2024","unstructured":"Kanaoka T, Wakui H, Yano Y, Nagasu H, Kanegae H, Nangaku M, et al. Factors affecting the sodium-glucose cotransporter 2 inhibitors-related initial decline in glomerular filtration rate and its possible effect on kidney outcome in chronic kidney disease with type 2 diabetes: the japan chronic kidney disease database. Diabetes Obes Metab. 2024;26(7):2905\u201314.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2928_CR9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"2928_CR10","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/j.ekir.2024.04.046","volume":"9","author":"A Shimizu","year":"2024","unstructured":"Shimizu A, Tsuboi N, Sasaki T, Haruhara K, Matsumoto K, Ueda H, et al. Glomerular hypertrophy and initial dip in estimated glomerular filtration rate following dapagliflozin administration. Kidney Int Rep. 2024;9(7):2282\u20135.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"2928_CR11","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1161\/01.HYP.0000146483.78994.56","volume":"44","author":"NL Cruden","year":"2004","unstructured":"Cruden NL, Fox KA, Ludlam CA, Johnston NR, Newby DE. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition. Hypertension. 2004;44(6):913\u20138.","journal-title":"Hypertension"},{"issue":"10","key":"2928_CR12","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/ki.2008.647","volume":"75","author":"M Kakoki","year":"2009","unstructured":"Kakoki M, Smithies O. The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int. 2009;75(10):1019\u201330.","journal-title":"Kidney Int"},{"issue":"1","key":"2928_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1006\/bbrc.1997.7999","volume":"243","author":"E Schremmer-Danninger","year":"1998","unstructured":"Schremmer-Danninger E, Offner A, Siebeck M, Roscher AA. B1 bradykinin receptors and carboxypeptidase M are both upregulated in the aorta of pigs after LPS infusion. Biochem Biophys Res Commun. 1998;243(1):246\u201352.","journal-title":"Biochem Biophys Res Commun"},{"issue":"13-14","key":"2928_CR14","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/S1567-5769(02)00174-1","volume":"2","author":"F Spillmann","year":"2002","unstructured":"Spillmann F, Altmann C, Scheeler M, Barbosa M, Westermann D, Schultheiss HP, et al. Regulation of cardiac bradykinin B1- and B2-receptor mRNA in experimental ischemic, diabetic, and pressure-overload-induced cardiomyopathy. Int Immunopharmacol. 2002;2(13\u201314):1823\u201332.","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"2928_CR15","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1096\/fj.04-3508fje","volume":"19","author":"V Griol-Charhbili","year":"2005","unstructured":"Griol-Charhbili V, Messadi-Laribi E, Bascands JL, Heudes D, Meneton P, Giudicelli JF, et al. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J. 2005;19(9):1172\u20134.","journal-title":"FASEB J"},{"issue":"3","key":"2928_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1161\/01.RES.88.3.275","volume":"88","author":"I Duka","year":"2001","unstructured":"Duka I, Kintsurashvili E, Gavras I, Johns C, Bresnahan M, Gavras H. Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. Circ Res. 2001;88(3):275\u201381.","journal-title":"Circ Res"},{"issue":"4S","key":"2928_CR17","first-page":"S117","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKDWG","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes CKDWG. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117\u2013314.","journal-title":"Kidney Int"},{"issue":"9","key":"2928_CR18","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/ejhf.2421","volume":"24","author":"FR Mc Causland","year":"2022","unstructured":"Mc Causland FR, Lefkowitz MP, Claggett B, Packer M, Senni M, Gori M, et al. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. Eur J Heart Fail. 2022;24(9):1591\u20138.","journal-title":"Eur J Heart Fail"},{"key":"2928_CR19","doi-asserted-by":"publisher","first-page":"1451450","DOI":"10.3389\/fmed.2024.1451450","volume":"11","author":"MM Rahman","year":"2024","unstructured":"Rahman MM, Rahman A, Nishiyama A. Potential renoprotective effects and possible underlying mechanisms of angiotensin receptor-neprilysin inhibitors in cardiorenal syndrome. Front Med (Lausanne). 2024;11:1451450.","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"2928_CR20","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1093\/ndt\/gfad098","volume":"38","author":"H Nishio","year":"2023","unstructured":"Nishio H, Ishii A, Yamada H, Mori KP, Kato Y, Ohno S, et al. Sacubitril\/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess. Nephrol Dial Transplant. 2023;38(11):2517\u201327.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2928_CR21","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41440-021-00819-7","volume":"45","author":"H Rakugi","year":"2022","unstructured":"Rakugi H, Kario K, Yamaguchi M, Sasajima T, Gotou H, Zhang J. Efficacy of sacubitril\/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study. Hypertens Res. 2022;45(5):824\u201333.","journal-title":"Hypertens Res"},{"issue":"9722","key":"2928_CR22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","volume":"375","author":"LM Ruilope","year":"2010","unstructured":"Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375(9722):1255\u201366.","journal-title":"Lancet"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02928-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02928-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02928-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:17:14Z","timestamp":1785842234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02928-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":22,"alternative-id":["2928"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02928-4","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures were approved by the research ethics committee of Tokyo Women\u2019s Medical University (No. 2024\u20130127) in accordance with the 1964 Declaration of Helsinki and its later amendments, or with comparable ethical standards.","order":2,"name":"Ethics","label":"Research involving human participants and\/or animals","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants included in the study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}